Your session is about to expire
← Back to Search
Pembrolizumab + Trebananib for Advanced Cancer
Study Summary
This trial is testing a combination of drugs to see if they are effective in treating advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have lesions that may bleed easily.I have been treated with trebananib or similar drugs.I am 18 years old or older.I have another cancer that is getting worse or needs treatment.I have an incurable metastatic solid tumor confirmed by tests.I have not had a heart attack, severe heart issues, or stroke in the last 6 months.I haven't had severe GI bleeding or uncontrollable blood clot issues in the last 3 months.I have not been treated with specific antibodies for my ovarian or colorectal cancer.I have active Hepatitis B or C.I haven't taken steroids or immunosuppressants in the last 7 days.I have not received any cancer-targeting antibody treatments in the last 4 weeks.I haven't had cancer treatment like chemotherapy, targeted therapy, or radiation in the last 2 weeks.I have had pneumonitis treated with steroids or have it now.I am currently being treated for an infection.I have an advanced form of melanoma, kidney, ovarian, or colorectal cancer that cannot be surgically removed.I am willing to provide a new tissue sample from my tumor for the study.My high blood pressure is not well-managed.I have a serious illness that is not under control.I have been diagnosed with an immunodeficiency condition, including HIV.I have an autoimmune disease treated with medication in the last 2 years.My organs are functioning well.I can carry out all my usual activities without help.I have not received a live vaccine in the last 30 days.I have a history of active tuberculosis.I have not taken strong immune boosters in the last 30 days.
- Group 1: Pembrolizumab + Trebananib (Melanoma)
- Group 2: Pembrolizumab + Trebananib (Renal Cell Carcinoma)
- Group 3: Pembrolizumab + Trebananib (Colorectal)
- Group 4: Pembrolizumab + Trebananib (Ovarian)
- Group 5: Pembrolizumab + Trebananib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical applications is Pembrolizumab typically employed for?
"Pembrolizumab is a powerful medication usually used to battle malignant neoplasms. It is also commonly taken as an intervention for unresectable melanoma, microsatellite instability high and cases where chemotherapy has failed or caused progression of the illness."
Does this medical trial currently have openings for participants?
"As of now, this clinical trial is not accepting any more participants. It was first listed on August 31st 2017 and the most recent edit occured March 22nd 2022. However, if you are seeking to join other studies, there are 2502 trials currently enrolling patients with solid tumors and 961 for Pembrolizumab specifically."
How many participants have joined the research endeavor thus far?
"As of March 22nd 2022, enrollment in this trial has ceased. It was initially advertised on August 31st 2017 and underwent its most recent edit at the above date. For those looking for alternative studies, there are 2502 admitting participants with solid tumors or advanced cases thereof as well as 961 trials offering Pembrolizumab to potential enrollees."
Are there any other trials involving Pembrolizumab that have been conducted?
"Currently, there are 961 clinical trials exploring the use of Pembrolizumab; 122 of these studies have advanced to their third phase. While a majority of them are located in Houston, Texas, this medication is being tested at 35 731 sites across the world."
How has Pembrolizumab demonstrated its efficacy in terms of patient safety?
"The safety of Pembrolizumab is rated at 1 on our scale because it is only in Phase 1 and thus has limited clinical data to support its efficacy or security."
Share this study with friends
Copy Link
Messenger